QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
OTCMKTS:HCYTD

H-CYTE (HCYTD) Stock Price, News & Analysis

$2.02
-1.98 (-49.50%)
(As of 07/11/2022)
Today's Range
$2.02
$2.77
50-Day Range
$2.02
$2.02
52-Week Range
$2.02
$77.00
Volume
400 shs
Average Volume
103 shs
Market Capitalization
$521,160.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

HCYTD stock logo

About H-CYTE Stock (OTCMKTS:HCYTD)

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.

HCYTD Stock Price History

HCYTD Stock News Headlines

H-CYTE (OTCMKTS:HCYTD) Trading Down 49.5%
H-CYTE (OTCMKTS:HCYTD) Stock Price Down 49.5%
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
H&R Block Coupons February 2024
Hyatt Hotels Corp Class A H
H-E-B Grocery Company
10-K: H-CYTE, INC.
HCYT H-CYTE, Inc.
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
H-CYTE Completes Acquisition of Jantibody
H-CYTE Announces 1-for-1,000 Reverse Stock Split
Should You Refrigerate Peanut Butter?
H-CYTE Inc (HCYT)
H-CYTE Names Michael Yurkowsky Chief Executive Officer
See More Headlines
Receive HCYTD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for H-CYTE and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
2/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & Medical Instruments
Sub-Industry
N/A
Current Symbol
OTCMKTS:HCYTD
Fax
N/A
Employees
8
Year Founded
N/A

Profitability

Net Income
$-4,800,000.00
Net Margins
-450.40%
Pretax Margin
-450.40%

Debt

Sales & Book Value

Annual Sales
$1.61 million
Book Value
($31.45) per share

Miscellaneous

Free Float
244,000
Market Cap
$521,160.00
Optionable
Not Optionable
Beta
1.12
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Michael W. Yurkowsky (Age 50)
    CEO & Director
    Comp: $180k
  • Mr. Jeremy Daniel (Age 46)
    Chief Financial Officer
    Comp: $200k
  • Dr. Tanya Rhodes Ph.D. (Age 61)
    Chief Scientific Officer
    Comp: $252k
  • Mr. Jeffery Wright CPA (Age 39)
    CPA, Controller & Principal Accounting Officer














HCYTD Stock Analysis - Frequently Asked Questions

How have HCYTD shares performed in 2024?

H-CYTE's stock was trading at $2.02 on January 1st, 2024. Since then, HCYTD shares have increased by 0.0% and is now trading at $2.02.
View the best growth stocks for 2024 here
.

How do I buy shares of H-CYTE?

Shares of HCYTD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:HCYTD) was last updated on 2/28/2024 by MarketBeat.com Staff